Your browser doesn't support javascript.
loading
Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022.
Ichihara, Eiki; Ochi, Nobuaki; Makimoto, Go; Kudo, Kenichiro; Harada, Daijiro; Ozaki, Yukinori; Nishio, Hiroshi; Tsuchihashi, Kenji; Miura, Yuji; Endo, Makoto; Yano, Shingo; Maruyama, Dai; Yoshinami, Tetsuhiro; Susumu, Nobuyuki; Takekuma, Munetaka; Motohashi, Takashi; Ito, Mamoru; Baba, Eishi; Uchino, Keita; Kimura, Takahiro; Kamiyama, Yutaro; Nakao, Shinji; Tamura, Shinobu; Nishimoto, Hitomi; Kato, Yasuhisa; Sato, Atsushi; Takano, Toshimi; Kubo, Toshio.
Afiliación
  • Ichihara E; Center for Clinical Oncology, Okayama University Hospital, 2-5-1 Shikata-Cho Kita-Ku, Okayama City,, 700-8558, Japan. ichiha-e@md.okayama-u.ac.jp.
  • Ochi N; Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
  • Makimoto G; Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
  • Kudo K; Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan.
  • Harada D; Department of Thoracic Oncology, NHO Shikoku Cancer Center, Matsuyama, Japan.
  • Ozaki Y; Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Nishio H; Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
  • Tsuchihashi K; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Miura Y; Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
  • Endo M; Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan.
  • Yano S; Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
  • Maruyama D; Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Yoshinami T; Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
  • Susumu N; Department of Obstetrics and Gynecology, International University of Health and Welfare Narita Hospital, Chiba, Japan.
  • Takekuma M; Department of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan.
  • Motohashi T; Department of Obstetrics and Gynecology, Tokyo Women's Medical University Hospital, Tokyo, Japan.
  • Ito M; Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Baba E; Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Uchino K; Department of Medical Oncology, NTT Medical Center Tokyo, Tokyo, Japan.
  • Kimura T; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Kamiyama Y; Department of Clinical Oncology/Hematology, The Jikei University School of Medicine, Tokyo, Japan.
  • Nakao S; Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan.
  • Tamura S; Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
  • Nishimoto H; Department of Nursing, Okayama University Hospital, Okayama, Japan.
  • Kato Y; Department of Drug Information, Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, Kanagawa, Japan.
  • Sato A; Department of Medical Oncology, Hirosaki University Graduate School of Medicine, Aomori, Japan.
  • Takano T; Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Kubo T; Department of Allergy and Respiratory Medicne, Okayama University Hospital, Okayama, Japan.
Int J Clin Oncol ; 29(4): 355-362, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38353907
ABSTRACT

BACKGROUND:

Granulocyte colony-stimulating factor (G-CSF) is commonly administered to cancer patients undergoing myelosuppressive chemotherapy, especially when incidence rate of febrile neutropenia (FN) surpasses 20%. While primary prophylaxis with G-CSF has been proven effective in preventing FN in patients with cancer, there is limited evidence regarding its efficacy in specifically, lung cancer. Our systematic review focused on the efficacy of G-CSF primary prophylaxis in lung cancer.

METHODS:

We extracted studies on non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) using the PubMed, Ichushi Web, and Cochrane Library databases. Two reviewers assessed the extracted studies for each type of lung cancer and conducted quantitative and meta-analyses of preplanned outcomes, including overall survival, FN incidence, infection-related mortality, quality of life, and musculoskeletal pain.

RESULTS:

A limited number of studies were extracted two on NSCLC and six on SCLC. A meta-analysis was not conducted owing to insufficient data on NSCLC. Two case-control studies explored the efficacy of primary prophylaxis with G-CSF in patients with NSCLC (on docetaxel and ramucirumab therapy) and indicated a lower FN frequency with G-CSF. For SCLC, meta-analysis of five studies showed no significant reduction in FN incidence, with an odds ratio of 0.38 (95% confidence interval 0.03-5.56, P = 0.48). Outcomes other than FN incidence could not be evaluated due to low data availability.

CONCLUSION:

Limited data are available on G-CSF prophylaxis in lung cancer. Primary prophylaxis with G-CSF may be weakly recommended in Japanese patients with NSCLC undergoing docetaxel and ramucirumab combination therapy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Carcinoma Pulmonar de Células Pequeñas / Neoplasias Pulmonares Tipo de estudio: Evaluation_studies / Guideline / Observational_studies / Risk_factors_studies / Systematic_reviews Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Int J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Carcinoma Pulmonar de Células Pequeñas / Neoplasias Pulmonares Tipo de estudio: Evaluation_studies / Guideline / Observational_studies / Risk_factors_studies / Systematic_reviews Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Int J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón